medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2022, Número 2

<< Anterior

Rev Mex Urol 2022; 82 (2)


Causa inusual de uropatía obstructiva: condrosarcoma pélvico

Corona-Montes VE, Fernández-Noyola G, Chablé-Montero F, Cervantes-Sánchez AM, Cruz-Reyes C, Borja-Menéndez DA, Rosas-Nava JE, Sánchez-Núñez JE

Idioma: Español
Referencias bibliográficas: 16
Paginas:
Archivo PDF: 186.14 Kb.


RESUMEN

Reportamos el caso de un paciente masculino de 37 años que presentó deterioro de la función renal secundario a tumoración pélvica. El abordaje diagnóstico reveló una tumoración dependiente del pubis correspondiente a un condrosarcoma mesenquimatoso que condicionaba obstrucción de la vía urinaria en los segmentos ureterales distales de manera bilateral, así como compresión vesical y sigmoidea. Los condrosarcomas mesenquimatosos son sarcomas dependientes de tejidos blandos con una incidencia extremadamente rara, la importancia clínica de nuestro reporte se debe a que los condrosarcomas, deben ser considerados en los diagnósticos diferenciales de uropatía obstructiva debido a su efecto compresor del tracto urinario. Realizamos un breve recuento del abordaje diagnóstico, plan terapéutico y pronóstico de esta patología.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lichtenstein L, Bernstein D. Unusual benignand malignant chondroid tumors of bone. Asurvey of some mesenchymal cartilage tumorsand malignant chondroblastic tumors, includinga few multicentric ones, as well as many atypicalbenign chondroblastomas and chondromyxoidfibromas. Cancer. 1959;12(6):1142–57.doi: https://doi.org/10.1002/1097-0 1 4 2 (195911/12) 12: 6 < 1142:: AID-CNCR2820120610>3.0.CO;2-D

  2. Lin O,, Zakowski MF. Cytology of SoftTissue, Bone, and Skin. In: ComprehensiveCytopathology. 3rd ed. Elsevier; 2008. p.Philadelphia.

  3. Ghafoor S, Hameed MR, Tap WD, HwangS. Mesenchymal chondrosarcoma: imagingfeatures and clinical findings. SkeletalRadiol. 2021;50(2):333–41. doi: https://doi.org/10.1007/s00256-020-03558-x

  4. Casali PG, Abecassis N, Bauer S, Biagini R,Bielack S, Bonvalot S, et al. Soft tissue andvisceral sarcomas: ESMO–EURACAN ClinicalPractice Guidelines for diagnosis, treatment andfollow-up†. Annals of Oncology. 2018;29:iv51–67. doi: https://doi.org/10.1093/annonc/mdy096

  5. Wein AJ, M.D AWP, M.D LRK, Novick AC.Campbell-Walsh Urologia/ Campbell-WalshUrology. 11th ed. Ed. Médica Panamericana;2008. 808 p.

  6. Xu J, Li D, Xie L, Tang S, Guo W. MesenchymalChondrosarcoma of Bone and Soft Tissue: ASystematic Review of 107 Patients in the Past 20Years. PLOS ONE. 2015 Apr 7;10(4):e0122216.doi: https://doi.org/10.1371/journal.pone.0122216

  7. Frezza AM, Cesari M, Baumhoer D, Biau D,Bielack S, Campanacci DA, et al. Mesenchymalchondrosarcoma: prognostic factors andoutcome in 113 patients. A EuropeanMusculoskeletal Oncology Society study. Eur JCancer. 2015;51(3):374–81. doi: https://doi.org/10.1016/j.ejca.2014.11.007

  8. Tsavaris O, Economopoulou P, Kotsantis I,Reppas L, Avgerinou C, Spathas N, et al. ClinicalBenefit of Pazopanib in a Patient with MetastaticChondrosarcoma: A Case Report and Review ofthe Literature. Frontiers in Oncology. 2018;8.doi: https://doi.org/10.3389/fonc.2018.00045

  9. Nakashima Y, Unni KK, Shives TC, Swee RG,Dahlin DC. Mesenchymal chondrosarcomaof bone and soft tissue. A review of 111cases. Cancer. 1986;57(12):2444–53.doi: https://doi.org/10.1002/1097-0142 (19860615) 57: 12 < 2444 :: AIDCNCR2820571233>3.0.CO;2-K

  10. Wang L, Motoi T, Khanin R, Olshen A, MertensF, Bridge J, et al. Identification of a novel,recurrent HEY1-NCOA2 fusion in mesenchymalchondrosarcoma based on a genome-widescreen of exon-level expression data. Genes,Chromosomes and Cancer. 2012;51(2):127–39.doi: https://doi.org/10.1002/gcc.20937

  11. Shapeero LG, Vanel D, Couanet D, ContessoG, Ackerman LV. Extraskeletal mesenchymalchondrosarcoma. Radiology. 1993;186(3):819–26. doi: https://doi.org/10.1148/radiology.186.3.8430193

  12. Mendenhall WM, Reith JD, ScarboroughMT, Stechmiller BK, Mendenhall NP.Mesenchymal Chondrosarcoma. Int J PartTher. 2016;3(2):300–4. doi: https://doi.org/10.14338/IJPT-16-00019.1

  13. Tansir G, Rastogi S, Barwad A, Dhamija E. Longlasting response with trabectedin monotherapyin relapsed metastatic mesenchymalchondrosarcoma. Clinical Sarcoma Research.2020;10(1):16. doi: https://doi.org/10.1186/s13569-020-00138-4

  14. Kawai A, Araki N, Sugiura H, Ueda T,Yonemoto T, Takahashi M, et al. Trabectedinmonotherapy after standard chemotherapyversus best supportive care in patients withadvanced, translocation-related sarcoma: arandomised, open-label, phase 2 study. LancetOncol. 2015;16(4):406–16. doi: https://doi.org/10.1016/S1470-2045(15)70098-7

  15. Araki N, Takahashi S, Sugiura H, Ueda T,Yonemoto T, Takahashi M, et al. Retrospectiveinter- and intra-patient evaluation of trabectedinafter best supportive care for patients withadvanced translocation-related sarcoma afterfailure of standard chemotherapy. EuropeanJournal of Cancer. 2016;56:122–30. doi: https://doi.org/10.1016/j.ejca.2015.12.014

  16. Cesari M, Bertoni F, Bacchini P, Mercuri M,Palmerini E, Ferrari S. Mesenchymal chondrosarcoma.An analysis of patients treated at asingle institution. Tumori. 2007;93(5):423–7.




2020     |     www.medigraphic.com